An AI powered turn-key solution for MRI based interventional cardiology

Projektinformationen

TRACKR

ID Finanzhilfevereinbarung: 190140779

DOI

10.3030/190140779

Projekt abgeschlossen

EK-Unterschriftsdatum 8 März 2023

Startdatum 1 April 2023

Enddatum 31 Dezember 2025

Finanziert unter

• The European Innovation Council (EIC)

Gesamtkosten

€ 3 546 727,50

EU-Beitrag

€ 2 482 709,00

Koordiniert durch

NANO4IMAGING GMBH
Germany

Periodic Reporting for period 1 - TRACKR (An AI powered turn-key solution for MRI based interventional cardiology)

Berichtszeitraum: 2023-04-01 bis 2024-03-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Nano4Imaging (N4I) is a MedTech company specialized in MR based interventional procedures. We have previously successfully commercialized EmeryGlide, an MR compatible guidewire for cardiovascular procedures. In this project, we will deliver TRACKR – a ‘turn-key’ platform that provides the currently missing technologies for MRI guided interventional radiology. The TRACKR technology consists of: a) a coating platform based on proprietary MagnaFy technology. This nano-coating can be applied on any commercial interventional device (catheter, guide-wire, balloon) and enable their MR visibility. b) A REAL-TIME TRACKING SOFTWARE based on novel deep learning algorithms that allows real-time tracking of the MagnaFy coated devices during an interventions. Over 700million patients worldwide will benefit from our treatment without radiation and contrast agents.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

We have conducted animal studies in the United States, Ohio State University (OSU) to generate training data for our algorithm. We have successfully developed the first version of the TRACKR software prototype which is currently undergoing the clinical input & feedback process. This is crucial and serves as a basis for the further development of the required functionalities while performing the interventional MRI procedures.

Finally we are preparing to use clinical data from application of our current EmeryGlide in cardiovascular indications as a validation set for our algorithm, which will be required before FDA submission of the software.
Regarding the coating platform as part of TRACKR we have printed different marker patterns on catheters from Numed, Biotronik, Terumo and others. These devices have been used in procedures in animals (OSU), including abdominal stenting, PTA and genicular artery embolization. Markers have been interrogated at different MRI sequences in low-field (0.5T) up to 3T Siemens scanners. Finally a series of markers have been printed on a new exchange wire prototype by N4I and evaluated in phantom and animal experiments.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

We have signed a letter of intent (LoI) with Siemens Healthineers AG which enables us to develop a second generation version of our TRACKR Software that can be integrated into the MAGNETOM Application Platform of the market leader Siemens’ MRI Scanner Systems and gives us a broad market access. At the same we are elaborating with Philips a collaboration to train and test different marker profiles to explore guidance using their existing overlay system, which is used by some of our major customers.
The impact of our project potentially reaches beyond the immediate benefot for patients. By enabling interventions in the MRI suite, we will contribute to the breakthrough developments in the medical imaging industry such as the increased utilization of environmentally friendly MRI scanners.

Study2_CCT_Page1

Company Logo

Study2_CCT_Page2

Study2_CCT_Page4

Study1_Borm_Page1

Study1_Borm_Page4

Project Poster

Study1_Borm_Page2

Study1_Borm_Page3

Study2_CCT_Page3